Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
May 23, 2019
Publication date:
September 12, 2019
Applicant:
SHIRE-NPS PHARMACEUTICALS, INC.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
May 17, 2019
Publication date:
September 5, 2019
Applicant:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
May 14, 2019
Publication date:
August 29, 2019
Applicant:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
May 15, 2019
Publication date:
August 29, 2019
Applicant:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
September 25, 2018
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
September 25, 2018
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Application
Filed:
May 16, 2018
Publication date:
September 20, 2018
Applicant:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
June 19, 2018
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
June 12, 2018
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
June 5, 2018
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
June 5, 2018
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
May 29, 2018
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
May 29, 2018
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
May 29, 2018
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
May 22, 2018
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
May 22, 2018
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
May 22, 2018
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
May 22, 2018
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
May 15, 2018
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
May 15, 2018
Assignee:
Shire-NPS Pharmaceuticals, Inc.
Inventors:
Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch